MannKind (MNKD)
(Real Time Quote from BATS)
$4.65 USD
+0.10 (2.20%)
Updated Jun 5, 2024 10:33 AM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Brokerage Reports
MannKind Corporation [MNKD]
Reports for Purchase
Showing records 201 - 220 ( 228 total )
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
We are maintaining our HOLD recommendation and keeping our target price under review.
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
We see next Afrezza PDUFA between 22 and 26 months away, estimate MNKD needs another
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Lowered our rating to HOLD and put our 12-month target price under review.
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Afrezza has similar fate to Bydureon: FDA brings up new issues on second CRL, timelines pushed out
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Afrezza has similar fate to Bydureon: FDA brings up new issues on second CRL, timelines pushed out
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Reports 3Q10; with PDUFA two months away, hoping for no surprise requests by the FDA.
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Reports 2Q10 results; gets back on partnership mode while waiting for PDUFA #2
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
A rare, on time/earlier-than-expected, surprise: CRL response sent, accepted by FDA, new PDUFA set
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
ADA data still point to a better, faster insulin;we continue to expect Afrezza in the market in
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S